Jun 18, 2021

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

Starpharma (ASX:SPL) shows 99.9pc antiviral activity against three COVID-19 variants

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants," The Market Herald reports. Read the full article here.

 This contains certain forward-looking statements.